Childhood Constipation: Evaluation and Management

ABSTRACT

Constipation is a common problem in children. It is also a long-term problem persisting for many months to years in children. Approximately 95% of childhood constipation is functional in nature without any obvious cause. Evaluation of a child with constipation requires a thorough history and physical examination. Hirschsprung's disease is an important cause of constipation arising in infancy and requires a thorough diagnostic evaluation and surgical treatment. Treatment of functional constipation in children requires a well-designed plan and a team approach involving the child, parents, and a health care provider. Treatment involves education of the family about constipation and encopresis, fecal disimpaction, and long-term maintenance therapy of laxatives and behavioral modification. Laxatives such as magnesium hydroxide, lactulose, and mineral oil have been used in children for a long time. A new laxative, polyethylene glycol 3350, has been used successfully in children with constipation and encopresis. Several novel therapeutic interventions have been tried for children presenting with intractable constipation, refractory to conventional treatment.

Constipation - encopresis - children - laxatives

REFERENCES

• 1 Issenman R M, Hewson S, Pirhonen D, Taylor W, Tirosh A. Are chronic digestive complaints the result of abnormal dietary patterns?.  Am J Dis Child. 1987;  141 679-682
• 2 Loening-Baucke V. Constipation in children.  N Engl J Med. 1998;  339 1155-1156
• 3 Baker S S, Liptak G S, Colletti R B et al.. Constipation in infants and children: evaluation and treatment.  J Pediatr Gastroenterol Nutr. 1999;  29 612-626
• 4 Rasquin-Weber A, Hyman P E, Cucchiara S et al.. Childhood functional gastrointestinal disorders.  Gut. 1999;  45(suppl II) II60-II68
• 5 Loening-Baucke V. Encopresis.  Curr Opin Pediatr. 2002;  14 570-575
• 6 Swenson O. Hirschsprung's disease: a review.  Rev Pediatr. 2002;  109 914-918
• 7 Edery P, Lyonnet S, Mulligan L M et al.. Mutations of the RET proto-oncogene in Hirschsprung's disease.  Nature. 1994;  367 378-380
• 8 Georgeson K E, Cohen R D, Hebra A et al.. Primary laparoscopic-assisted endorectal colon pull-through for Hirschsprung's disease: a new gold standard.  Ann Surg. 1999;  229 678-682
• 9 Hyams J S, Treem W R, Etienne N L et al.. Effect of infant formula on stool characteristics of young infants.  Pediatrics. 1995;  95 50-54
• 10 Weaver L T, Steiner H. The bowel habits of young children.  Arch Dis Child. 1984;  59 649-652
• 11 Morais M B, Vitolo M R, Aquirre A NC et al.. Measurement of low dietary fiber intake as a risk factor for chronic constipation in children.  J Pediatr Gastroenterol Nutr. 1999;  29 132-135
• 12 Tolia V, Lin C H, Elitsur Y. A prospective randomized study with mineral oil and oral lavage solution for treatment of fecal impaction in children.  Aliment Pharmacol Ther. 1993;  7 523-529
• 13 Youssef N N, Peters J M, Henderson W, Schultz-Peters S, Lockhart D K, Di Lorenzo C. Dose response of PEG 3350 for the treatment of childhood fecal impaction.  J Pediatr. 2002;  141 410-414
• 14 Ismail E AR, Al-Mutairi G, Al-Anzy H. A fatal small dose of phosphate enema in a young child with no renal or gastrointestinal abnormality.  J Pediatr Gastroenterol Nutr. 2000;  30 220-221
• 15 Walker M, Warner B W, Brilli R J, Jacobs B R. Cardiopulmonary compromise associated with milk and molasses enema use in children.  J Pediatr Gastroenterol Nutr. 2003;  36 144-148
• 16 Staiano A, Simeone D, Del Giudice E, Miele E, Tozzi A, Toraldo C. Effect of the dietary fiber glucomannan on chronic constipation in neurologically impaired children.  J Pediatr. 2000;  136 41-45
• 17 Loening-Baucke V, Miele E, Staiano A. Fiber (glucomannan) is beneficial in the treatment of childhood constipation.  Pediatrics. 2004;  113 e258-e264
• 18 Iacono G, Cavataio F, Montalto G et al.. Intolerance of cow's milk and chronic constipation in children.  N Engl J Med. 1998;  339 1100-1104
• 19 Loening-Baucke V. Constipation in early childhood: patient characteristics, treatment, and long-term follow up.  Gut. 1993;  34 1400-1404
• 20 van Ginkel R, Reitsma J B, Buller H A, Van Wijk M P, Taminiau J A, Benninga M A. Childhood constipation: longitudinal follow-up beyond puberty.  Gastroenterology. 2003;  125 357-363
• 21 DiPalma J A, DeRidder P H, Orlando R C et al.. A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative.  Am J Gastroenterol. 2000;  95 446-449
• 22 Pashankar D S, Bishop W P. Efficacy and optimal dose of daily polyethylene glycol 3350 for treatment of constipation and encopresis in children.  J Pediatr. 2001;  139 428-432
• 23 Gremse D A, Hixon J, Crutchfield A. Comparison of polyethylene glycol 3350 and lactulose for treatment of chronic constipation in children.  Clin Pediatr. 2002;  41 225-229
• 24 Erickson B A, Austin J C, Cooper C S, Boyt M A. Polyethylene glycol 3350 for constipation in children with dysfunctional elimination.  J Urol. 2003;  170 1518-1520
• 25 Loening-Baucke V, Krishna R, Pashankar D S. Polyethylene glycol 3350 without electrolytes for the treatment of functional constipation in infants and toddlers.  J Pediatr Gastroenterol Nutr. 2004;  39 536-539
• 26 Loening-Baucke V. Polyethylene glycol without electrolytes for children with constipation and encopresis.  J Pediatr Gastroenterol Nutr. 2002;  34 372-377
• 27 Pashankar D S, Bishop W P, Loening-Baucke V. Long-term efficacy of polyethylene glycol 3350 for the treatment of chronic constipation in children with and without encopresis.  Clin Pediatr. 2003;  42 815-819
• 28 Pashankar D S, Loening-Baucke V, Bishop W. Safety of polyethylene glycol 3350 for the treatment of chronic constipation in children.  Arch Pediatr Adolesc Med. 2003;  157 661-664
• 29 Brazzelli M, Griffiths P. Behavioural and cognitive interventions with or without other treatments for defaecation disorders in children.  Cochrane Database Syst Rev. 2001;  4 CD002240
• 30 Ciamarra P, Nurko S, Barksdale E, Fishman S, Di Lorenzo C. Internal anal sphincter achalasia in children: clinical characteristics and treatment with Clostridium botulinum toxin.  J Pediatr Gastroenterol Nutr. 2003;  37 315-319
• 31 Curry J I, Osborne A, Malone P SJ. The MACE procedure: experience in the United Kingdom.  J Pediatr Surg. 1999;  34 338-340
• 32 Youssef N N, Barksdale Jr E, Griffiths J M, Flores A F, Di Lornzo C. Management of intractable constipation with antegrade enemas in neurologically intact children.  J Pediatr Gastroenterol Nutr. 2002;  34 402-405
• 33 Rivera M T, Kugathasan S, Berger W, Werlin S L. Percutaneous colonoscopic cecostomy for management of chronic constipation in children.  Gastrointest Endosc. 2001;  53 225-228
• 34 Churchill B M, De Ugarte D A, Atkinson J B. Left-colon antegrade continence enema (LACE) procedure for fecal incontinence.  J Pediatr Surg. 2003;  38 1778-1780
• 35 De Caluwé D, Yoneda A, Akl U, Puri P. Internal anal sphincter achalasia: outcome after internal sphincter myectomy.  J Pediatr Surg. 2001;  36 736-738
• 36 Woodward M N, Foley P, Cusick E L. Colostomy for treatment of functional constipation in children: a preliminary report.  J Pediatr Gastroenterol Nutr. 2004;  38 75-78
• 37 Youssef N N, Pensabene L, Barksdale Jr E, Di Lorenzo C. Is there a role for surgery beyond colonic aganglionosis and anorectal malformations in children with intractable constipation?.  J Pediatr Surg. 2004;  39 73-77